HealthEquity, Inc.’s HQY share price has dipped by 17.07%, which has investors questioning if this is right time to buy.

For the quarter ended January 2025, HealthEquity (HQY) reported revenue of $311.82 million, up 18.8% over the same period last year. EPS came in at $0.69, compared to $0.63 in the year-ago quarter.

These fell short of expectations on several metrics. HealthEquity divulged its fourth-quarter and full-year fiscal 2024 results just after market close on Tuesday. These showed that the company ...

HealthEquity (NASDAQ:HQY – Get Free Report) was upgraded by analysts at Raymond James from an “outperform” rating to a “strong-buy” rating in a note issued to investors on Tuesday, MarketBeat.com ...

HealthEquity (HQY) stock dropped over 13% aftermarket trading following the company’s earnings announcement. Despite the decline, the company ...

HealthEquity stock drops after mixed Q4 results despite 18.8% revenue growth. Click here to find out why HQY stock is a Hold.

Despite its strong performance, HealthEquity faces several challenges ... You can also see if HQY appears on our undervalued or overvalued stock lists. These tools provide a clearer picture ...

investors and analysts are closely monitoring its performance and future prospects. According to InvestingPro analysis, HealthEquity’s stock currently appears to be trading near its Fair Value, with ...

HealthEquity, Inc. HQY has been gaining from its business model and strategy. The optimism, led by a solid third-quarter fiscal 2025 performance ... highlights the one stock set to climb highest.